Home › Companies › Phathom Pharmaceuticals, Inc. › 2024-2025

Phathom Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Phathom Pharmaceuticals, Inc.’s Form 8-K, filed 2025-06-09 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
141Asset managers
1,012Fund votes
2025-06-03Meeting date

Proxy season: 2024-2025 2025-2026

Explore Phathom Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Phathom Pharmaceuticals, Inc.

These tallies are Phathom Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-09 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Phathom Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2025-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Heidi Kunz	34,023,182	--	--	451,384	17,427,382	Majority: yes
Elect Director: James Topper, M.D., Ph.D.	26,884,171	--	--	7,590,395	17,427,382	Majority: yes
Proposal 2: Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2025:	51,670,346	177,785	53,817	--	--	Majority: yes
Proposal 3: Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers:	24,584,781	8,704,739	1,185,046	--	17,427,382	Majority: yes

Source: Phathom Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2025-06-09 — read the filing on EDGAR.

How asset managers voted at the Phathom Pharmaceuticals, Inc. 2024-2025 meeting

Each item below shows how the 141 asset managers that disclosed a Phathom Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Phathom Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 11 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%AGAINST 26%

FOR: 24,584,781AGAINST: 8,704,739

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers:”): 24,584,781 for, 8,704,739 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,638,070 outstanding shares: 35% for, 12% against (47.8% of the company cast a for/against vote).

The 140 asset managers below cast 74% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 73%AGAINST 26%

FOR: 72.6%AGAINST: 26.0%ABSTAIN: 1.4%NOT VOTED: 0.0%

Largest asset managers voting on “To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").” at Phathom Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Vote
Frazier Life Sciences Management, L.P.	12,466,489	0	0	For
Medicxi Ventures Management (Jersey) Ltd	7,464,572	0	0	For
Invesco	0	5,627,672	0	Against
Carlyle Group Inc.	3,496,808	0	0	For
JENNISON ASSOCIATES LLC	0	3,189,836	0	Against
Ensign Peak Advisors, Inc	2,494,309	0	0	For
NEA Management Company, LLC	1,960,169	0	0	For
WASATCH ADVISORS LP	1,701,627	0	0	For
Prudential/PGIM	566,000	1,003,653	0	Against
WASATCH FUNDS TRUST	1,567,663	0	0	For
Avidity Partners Management LP	0	800,000	0	Against
Vanguard	792,687	0	0	For
Charles Schwab	0	695,884	0	Against
Simplify Exchange Traded Funds	0	0	681,935	Abstain
JACOBS LEVY EQUITY MANAGEMENT, INC	512,605	0	0	For
BlackRock	470,400	18,915	0	For
GW&K Investment Management, LLC	0	460,879	0	Against
StepStone Group LP	422,085	0	0	For
State Street	406,236	2,389	0	For
Woodline Partners LP	401,814	0	0	For
John Hancock	27,629	264,016	0	Against
Northern Trust	230,277	0	0	For
Equitable	58,811	160,784	0	Against
SEI	0	158,801	0	Against
Fidelity	138,086	12,721	0	For

Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.

2. To approve a proposal for the frequency of future non-binding advisory votes on the compensation of the named executive officers ("say-on-frequency").

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.8% fund support · no official result

ONE YEAR 59%1 YEAR 36%

The 131 asset managers below cast 99.8% of the shares they voted on this item FOR (11,784 for, 20 against).

FOR: 11,784 (0.0%)AGAINST: 20 (0.0%)ABSTAIN: 240 (0.0%)ONE YEAR: 28,543,664 (59.0%)1 YEAR: 17,299,908 (35.8%)3 YEARS: 2,495,309 (5.2%)NOT VOTED: 500 (0.0%)

Largest asset managers voting on “To approve a proposal for the frequency of future non-binding advisory votes on the compensation of the named ” at Phathom Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Frazier Life Sciences Management, L.P.	0	0	0	0	One Year
Medicxi Ventures Management (Jersey) Ltd	0	0	0	0	1 Year
Invesco	0	0	0	0	One Year
Carlyle Group Inc.	0	0	0	0	One Year
JENNISON ASSOCIATES LLC	0	0	0	0	1 Year
Ensign Peak Advisors, Inc	0	0	0	0	3 Years
NEA Management Company, LLC	0	0	0	0	1 Year
WASATCH ADVISORS LP	0	0	0	0	One Year
Prudential/PGIM	0	0	0	0	One Year
WASATCH FUNDS TRUST	0	0	0	0	One Year
Avidity Partners Management LP	0	0	0	0	1 Year
Vanguard	0	0	0	0	One Year
Charles Schwab	0	0	0	0	1 Year
JACOBS LEVY EQUITY MANAGEMENT, INC	0	0	0	0	1 Year
BlackRock	0	0	0	0	1 Year
GW&K Investment Management, LLC	0	0	0	0	1 Year
State Street	0	0	0	0	One Year
Woodline Partners LP	0	0	0	0	One Year
John Hancock	0	0	0	0	1 Year
Northern Trust	0	0	0	0	1 Year
Equitable	0	0	0	0	One Year
SEI	0	0	0	0	1 Year
Fidelity	0	0	0	0	One Year
Wellington	0	0	0	0	1 Year
BANK OF AMERICA NA	0	0	0	0	1 Year

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

3. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 51,670,346AGAINST: 177,785

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal”): 51,670,346 for, 177,785 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,638,070 outstanding shares: 74% for, 0.3% against (74% of the company cast a for/against vote).

The 42 asset managers below cast 100% of the shares they voted on this item FOR (8,041,969 for, 0 against).

FOR 100%

FOR: 8,041,969 (100.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ” at Phathom Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Vote
Invesco	2,543,209	For
WASATCH FUNDS TRUST	1,567,663	For
Prudential/PGIM	1,001,623	For
Vanguard	777,789	For
Simplify Exchange Traded Funds	681,935	For
Charles Schwab	347,939	For
John Hancock	277,799	For
Equitable	219,595	For
BlackRock	111,243	For
Fidelity	97,672	For
SEI	79,380	For
Goldman Sachs	56,762	For
QUANTITATIVE MASTER SERIES LLC	41,110	For
Lincoln Financial	30,100	For
AMG Funds IV	28,698	For
PFM Multi-Manager Series Trust	28,600	For
Northern Trust	24,666	For
ETFis Series Trust I	19,857	For
Pacific Life	18,399	For
Bridge Builder Trust	16,048	For
Jackson National	15,318	For
AIG/SunAmerica	11,129	For
RBB FUND, INC.	9,491	For
ProShares	9,086	For
DWS	6,090	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

4. To elect two class II directors to hold office until the 2026 Annual Meeting of Stockholders: Heidi Kunz

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 34,023,182WITHHELD: 451,384

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Heidi Kunz”): 34,023,182 for, 451,384 withheld, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,638,070 outstanding shares: 48.9% for, 0.7% withheld (49.5% of the company cast a for/withheld vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (7,314,444 for, 0 against).

FOR 99.3%

FOR: 7,314,444 (99.4%)ABSTAIN: 45,590 (0.6%)

Largest asset managers voting on “To elect two class II directors to hold office until the 2026 Annual Meeting of Stockholders: Heidi Kunz” at Phathom Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Abstain	Vote
Invesco	2,543,209	0	For
WASATCH FUNDS TRUST	1,567,663	0	For
Prudential/PGIM	1,001,623	0	For
Vanguard	777,789	0	For
Charles Schwab	347,939	0	For
John Hancock	277,799	0	For
Equitable	174,005	45,590	For
BlackRock	111,243	0	For
Fidelity	97,672	0	For
SEI	79,380	0	For
Goldman Sachs	56,762	0	For
QUANTITATIVE MASTER SERIES LLC	41,110	0	For
Lincoln Financial	30,100	0	For
AMG Funds IV	28,698	0	For
PFM Multi-Manager Series Trust	28,600	0	For
Northern Trust	24,666	0	For
ETFis Series Trust I	19,857	0	For
Pacific Life	18,399	0	For
Bridge Builder Trust	16,048	0	For
Jackson National	15,318	0	For
AIG/SunAmerica	11,129	0	For
RBB FUND, INC.	9,491	0	For
ProShares	9,086	0	For
DWS	6,090	0	For
Global X	5,622	0	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

5. To elect two class II directors to hold office until the 2026 Annual Meeting of Stockholders: James Topper, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%

FOR: 26,884,171WITHHELD: 7,590,395

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: James Topper, M.D., Ph.D.”): 26,884,171 for, 7,590,395 withheld, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 69,638,070 outstanding shares: 39% for, 11% withheld (49.5% of the company cast a for/withheld vote).

The 41 asset managers below cast 100% of the shares they voted on this item FOR (3,972,370 for, 0 against).

FOR 54.0%ABSTAIN 46.0%

FOR: 3,972,370 (54.0%)ABSTAIN: 3,387,664 (46.0%)

Largest asset managers voting on “To elect two class II directors to hold office until the 2026 Annual Meeting of Stockholders: James Topper, M.” at Phathom Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Abstain	Vote
Invesco	0	2,543,209	Abstain
WASATCH FUNDS TRUST	1,567,663	0	For
Prudential/PGIM	1,001,623	0	For
Vanguard	777,789	0	For
Charles Schwab	0	347,939	Abstain
John Hancock	264,016	13,783	For
Equitable	13,221	206,374	Abstain
BlackRock	111,243	0	For
Fidelity	97,672	0	For
SEI	0	79,380	Abstain
Goldman Sachs	0	56,762	Abstain
QUANTITATIVE MASTER SERIES LLC	41,110	0	For
Lincoln Financial	30,100	0	For
AMG Funds IV	28,698	0	For
PFM Multi-Manager Series Trust	0	28,600	Abstain
Northern Trust	0	24,666	Abstain
ETFis Series Trust I	0	19,857	Abstain
Pacific Life	18,399	0	For
Bridge Builder Trust	16,048	0	For
Jackson National	0	15,318	Abstain
AIG/SunAmerica	0	11,129	Abstain
RBB FUND, INC.	0	9,491	Abstain
ProShares	0	9,086	Abstain
DWS	0	6,090	Abstain
Global X	0	5,622	Abstain

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

6. NOMINEE WITHDRAWN

DIRECTOR ELECTIONS

100% fund support · no official result

FOR 66%ABSTAIN 34%

The 15 asset managers below cast 100% of the shares they voted on this item FOR (1,307,519 for, 0 against).

FOR: 1,307,519 (66.2%)ABSTAIN: 668,534 (33.8%)

Largest asset managers voting on “NOMINEE WITHDRAWN” at Phathom Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Abstain	Vote
Prudential/PGIM	1,001,623	0	For
Charles Schwab	0	347,939	Abstain
John Hancock	264,016	13,783	For
BlackRock	0	111,243	Abstain
SEI	0	79,380	Abstain
QUANTITATIVE MASTER SERIES LLC	0	41,110	Abstain
AMG Funds IV	28,698	0	For
PFM Multi-Manager Series Trust	0	28,600	Abstain
Bridge Builder Trust	0	16,048	Abstain
Jackson National	0	15,318	Abstain
Fidelity	12,721	0	For
RBB FUND, INC.	0	9,491	Abstain
Global X	0	5,622	Abstain
Innovator ETFs Trust	243	0	For
Advisors' Inner Circle Fund III	218	0	For

7. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

ONE YEAR 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR: 133,424 (100.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Phathom Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
JPMorgan	0	0	0	0	One Year
Brighthouse	0	0	0	0	One Year

8. TO APPROVE A PROPOSAL FOR THE FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS (SAY-ON-FREQUENCY&QUOT). &QUOT

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1 YEAR 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1 YEAR: 436 (100.0%)

Largest asset managers voting on “TO APPROVE A PROPOSAL FOR THE FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON THE COMPENSATION OF THE NAMED ” at Phathom Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Advisors' Inner Circle Fund III	0	0	0	0	1 Year
L2 Asset Management, LLC	0	0	0	0	1 Year

Largest Phathom Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked by the number of Phathom Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 69,638,070 shares outstanding at the time of that meeting.

Top Phathom Pharmaceuticals, Inc. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Frazier Life Sciences Management, L.P.	17.90%
2	Medicxi Ventures Management (Jersey) Ltd	10.72%
3	Invesco	8.08%
4	Carlyle Group Inc.	5.02%
5	JENNISON ASSOCIATES LLC	4.58%
6	Ensign Peak Advisors, Inc	3.58%
7	NEA Management Company, LLC	2.81%
8	WASATCH ADVISORS LP	2.44%
9	Prudential/PGIM	2.25%
10	WASATCH FUNDS TRUST	2.25%

Reported Phathom Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Phathom Pharmaceuticals, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
James N. Topper	20.72%	13D
Frazier Life Sciences IX, L.P.	8.37%	13D
Invesco	5.24%	13F
Carlyle Group Inc.	5.02%	13G
BlackRock	4.77%	13F
Vanguard Group	3.99%	13F
Morgan Stanley	1.62%	13F
Geode Capital	1.46%	13F
State Street	1.29%	13F
Millennium Management	0.75%	13F

Percentages above are of 69,638,070 shares outstanding, as reported by Phathom Pharmaceuticals, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Phathom Pharmaceuticals, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Phathom Pharmaceuticals, Inc.'s shareholder meeting held 2025-06-03, in the 2024-2025 proxy season, 141 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,012 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve the compensation of the named executive officers on a non-binding advisory basis… — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Phathom Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-09.

Phathom Pharmaceuticals, Inc. proxy season coverage: 2024-2025 (this page) · 2025-2026.